Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, August 14, 2022 · 586,029,865 Articles · 3+ Million Readers

Alterola Biotech Inc. (OTC Markets ABTI) Announces Stop Transfer Legend Application to certain shares

The Board of Directors (the “Board”) of Alterola Biotech Inc. (OTC Markets: ABTI) or (the “Company”) announces that the Company is updating its Share Register.


BIRKENHEAD, UNITED KINGDOM, July 6, 2022 / -- The Board of Directors (the “Board”) of Alterola Biotech Inc. (OTC Markets: ABTI) or (the “Company”) announces that the Company, following an internal investigation, is updating its Share Register.

In recent weeks, the Company has conducted a review of its shareholder list and, as a consequence, has identified several historical transactions / holdings that do not meet the appropriate requirements to qualify as legitimate transactions / holdings. As a result, the Company has, as an interim measure, and in agreement with Legal Counsel and the appointed exclusive Transfer Agent, added a “Stop Transfer” legend on all affected shares– i.e. those
listed on the Company Share Register as being held by or derived from:

1. London Pharma Holdings Ltd (UK Company Number: 10712042)
2. Future Trends Ltd (UK Company Number: 12021179)
3. Total Investment Holding Ltd (UK Company Number: 09097841)
4. Cennet Investments Limited (UK Company Number: 12649701)
5. Bulls Run Investments Limited (Hong Kong)
6. Norfolk Heights Ltd (Seychelles, IBC Number: 164017)
7. Crystalmount Limited (Seychelles, IBC Number: 144219)

Any investor who is concerned, and has acquired shares from any of these entities, is currently engaged in discussions, or is offered Securities held by the entities should immediately contact the Company at or write to the Company at the address given below:

Alterola Biotech Inc.
47 Hamilton Square
CH 41 5AR
United Kingdom

Further action in respect of the affected shares will be taken by the Company pending the appropriate Legal and Regulatory advice and any further action will be subject to additional notifications and filings as deemed appropriate in due course.


Powered by EIN Presswire
Distribution channels: Science

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release